ANIP: Rare disease focus, sales force expansion, and clinical data drive strong growth outlook
The company is rapidly expanding its rare disease portfolio, with Cortrophin Gel and ILUVIEN driving growth and a strong generics business funding further investment. Revised 2026 guidance reflects Q1 headwinds, but robust sales force expansion and clinical initiatives support confidence in long-te…
The company is rapidly expanding its rare disease portfolio, with Cortrophin Gel and ILUVIEN driving growth and a strong generics business funding further investment. Revised 2026 guidance reflects Q1 headwinds, but robust sales force expansion and clinical initiatives support confidence in long-te…